Volume 59, Issue 2, Pages 244-249 (February 2011) Effect of Dutasteride on Prostate Biopsy Rates and the Diagnosis of Prostate Cancer in Men with Lower Urinary Tract Symptoms and Enlarged Prostates in the Combination of Avodart and Tamsulosin Trial  Claus G. Roehrborn, Gerald L. Andriole, Timothy H. Wilson, Ramiro Castro, Roger S. Rittmaster  European Urology  Volume 59, Issue 2, Pages 244-249 (February 2011) DOI: 10.1016/j.eururo.2010.10.040 Copyright © 2010 Terms and Conditions

Fig. 1 Time to prostate cancer adverse effect by treatment group. Kaplan-Meier graph for time to prostate cancer diagnosis by treatment group. Time to prostate cancer was significantly longer for combination therapy versus tamsulosin monotherapy (p=0.006) and dutasteride monotherapy versus tamsulosin monotherapy (p=0.021). The relative risk reduction (RRR) was 43% for combination versus tamsulosin (95% confidence interval [CI], 15–62%) and 37% for dutasteride versus tamsulosin (95% CI, 6–57%). When results from the dutasteride arms were pooled, there was a 1.5% absolute risk reduction and a 40% RRR versus tamsulosin (95% CI, 16–57%; p=0.002). European Urology 2011 59, 244-249DOI: (10.1016/j.eururo.2010.10.040) Copyright © 2010 Terms and Conditions

Fig. 2 Gleason score of prostate cancer diagnosed in the CombAT study. Number of prostate cancer cases and Gleason score distribution by treatment group and time period. Numbers above bars indicate total number of cancers detected by treatment group; numbers within bars report occurrence by Gleason score. European Urology 2011 59, 244-249DOI: (10.1016/j.eururo.2010.10.040) Copyright © 2010 Terms and Conditions